$VRSK

Mann Elizabeth sold $77K of VRSK

Mann Elizabeth (Chief Financial Officer) sold 400 shares of Verisk Analytics, Inc. (VRSK) at $192.11 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mann Elizabeth
Published Jul 15, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

Because it is a planned open-market sale and not a buy or a non-routine event, it provides little new information about Verisk’s near-term performance.

02

Market read

Traders may note the disclosure for sentiment monitoring, but it is unlikely to drive a fundamental repricing.

03

What to watch

The transaction size ($76.8k) is small relative to typical large-cap trading flows, and 10b5-1 plans are designed to reduce timing-based inference.

Relevance 2/10Novelty 2/10Timing: Filed 2026-07-15, after-hours SEC Form 4 disclosure

Background

The article is a primary-source SEC Form 4 insider transaction by Verisk’s CFO, Elizabeth Mann, marked as a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Verisk CFO Elizabeth Mann filed a Form 4 selling 400 shares at $192.11 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely negligible immediate price impact; any effect is more about optics than new company information.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly noted as pre-arranged under Rule 10b5-1, and contains no new operational, financial, or regulatory facts.

Market effects

No sector read-through; insider sale does not change Verisk’s business outlook.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, some traders may interpret insider selling as mild caution, especially if clustered with other recent sales.

Key entities

  • Verisk Analytics, Inc.

    Company whose CFO insider sale is disclosed on SEC Form 4.

  • Elizabeth Mann

    Chief Financial Officer who sold 400 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer